BridgeBio Pharma, Inc, trading under the symbol BBIO, is a biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for genetic diseases. Founded in 2015, the company is based in Palo Alto, California, and operates worldwide.
With the genetic diseases being the company's core focus, BridgeBio mainly targets specific mutations in a patient that can cause or significantly contribute to a particular disease. They strive to create therapies by identifying the genetically-driven conditions' right target and develop the best possible delivery methodology.
BridgeBio’s approach is patient-oriented — listening to patients, their families, and their physicians, studying the disease's natural history, and comprehending the genetic science that leads to disease manifestations. The combination of scientific, clinical, and commercial expertise helps the company understand, confront, and potentially change the course of terrible diseases.
To translate scientific discoveries to the clinic rapidly, BridgeBio has built a unique portfolio of product candidates which include more than 30 development programs ranging from early discovery to late-stage development. Notably, the company's therapies in dermatology, cardiology, neurology, endocrinology, renal disease, and ophthalmology are substantially advancing in clinical trials.
The company follows a novel business model where each product candidate is developed by a separate subsidiary. This innovative model aids in focusing the energy and expertise on each separate program while keeping resource allocation efficient and execution-focused.
BridgeBio's mission is written in its name: it serves as a bridge from the discovery of genetic diseases to a future where the diseases are treatable. Their ultimate goal being, transforming the lives of patients who currently have little to no therapeutic options.
The journey to bring impactful medicines to patients is a long and challenging one. But with an excellent leadership team, comprising biotech industry veterans and successful entrepreneurs, and the dedication to scientific innovation, BridgeBio is committed to the advancement of genetic medicines. By pursuing a wide variety of genetic diseases with substantial unmet medical needs and by tirelessly working to develop pioneering treatments, BridgeBio Pharma is making a significant impact in the pharmaceutical industry as well as in the lives of those who need it most.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
BridgeBio Pharma will present 28 abstracts on acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) at the XX International Symposium on Amyloidosis (ISA) 2026. The data will highlight acoramidis's differentiated clinical profile, including its safety and efficacy in patients with chronic kidney disease, effects on cardiorenal function, and real-world outcomes compared to other treatments. These presentations aim to reinforce acoramidis as a leading first-line treatment option for ATTR-CM.
BridgeBio Pharma shareholders saw a 24.1% return over the past year, reflecting differing analyst views on its potential. Bullish forecasts focused on Attruby's momentum and late-stage programs, while cautious views highlighted reliance on a single franchise and high operating costs. The company's Q3 2026 revenue of US$353.2 million supported growth, but the profitability thesis remains unproven as it still reported a significant loss.
BridgeBio Pharma, Inc. announced equity grants to 80 new employees, consisting of restricted stock units for an aggregate of 147,578 shares of the company's common stock. These awards were approved by the compensation committee on November 5, 2026, as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants will vest over time, with the first portion vesting on November 16, 2027, subject to continued employment.
A new report by DelveInsight details the Achondroplasia pipeline for 2026, highlighting over 10 key companies developing novel treatments. The report outlines ongoing clinical trials, therapeutic mechanisms, and market growth prospects. Key companies include BioMarin Pharmaceuticals and BridgeBio/QED Therapeutics, with several therapies nearing significant regulatory milestones like FDA approvals.
BridgeBio Pharma, Inc. announced upcoming presentations at the American Heart Association (AHA) Scientific Sessions 2026, where new data on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared. The data aims to reinforce acoramidis's clinical profile as a first-line treatment for ATTR-CM, highlighting its near-complete TTR stabilization. Presentations will cover various aspects including diagnostic methods, effects on heart failure events, and risk of hospitalizations in ATTR-CM patients.
BridgeBio Pharma, Inc. will present new data on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM) at the American Heart Association Scientific Sessions 2026. The presentations will highlight acoramidis's differentiated clinical profile, reinforcing its position as a first-line treatment for ATTR-CM, and include moderated posters and poster presentations on the drug's effects on heart failure events and diagnostic approaches. The data further support acoramidis (Attruby® / BEYONTTRA®) as a near-complete TTR stabilizer approved for ATTR-CM treatment.
BridgeBio Pharma reported strong financial results for Q3 2026, with total revenues of $353.2 million, driven by acoramidis sales and a $75 million milestone from Bayer. The company is preparing for three significant product launches—BBP-418, infigratinib, and encaleret—all under priority review with the FDA. BridgeBio remains confident in its acoramidis franchise, projecting $4 billion in peak-year sales, and highlights compelling real-world evidence differentiating it from competitors.